Literature DB >> 36210419

Modeling of Benign Prostatic Hyperplasia in Rats with a High Dose of Testosterone.

I V Sorokina1,2, N A Zhukova3, Yu V Meshkova3, D S Baev3, T G Tolstikova3, M A Bakarev4, E L Lushnikova4.   

Abstract

In order to optimize the testosterone model of benign prostatic hyperplasia, we studied the effect of castration and different doses of testosterone on the induction of the proliferative process in the prostate of Wistar rats. It was shown that 4-week subcutaneous administration of testosterone propionate in a dose of 20 mg/kg causes pronounced proliferative and hemodynamic disorders in the dorsolateral gland morphologically similar in castrated and non-castrated males. Administration of testosterone in a dose of 3 mg/kg had no significant effect on the dynamics of the pathological process in non-operated rats and normalized the structure of the gland in castrated animals. Morphological study showed that castration of males provides no visible advantages in reproducing the testosterone model of benign prostatic hyperplasia. The proposed non-traumatic modification of the model with a high dose of testosterone has good reproducibility and sensitivity to therapeutic agents, as shown by the example of finasteride.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  benign prostatic hyperplasia; castration; finasteride; rats; testosterone model

Mesh:

Substances:

Year:  2022        PMID: 36210419     DOI: 10.1007/s10517-022-05613-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.737


  10 in total

Review 1.  Testosterone and Benign Prostatic Hyperplasia.

Authors:  Giulia Rastrelli; Linda Vignozzi; Giovanni Corona; Mario Maggi
Journal:  Sex Med Rev       Date:  2019-02-22

2.  Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative.

Authors:  Xian Yang; Liuliu Yuan; Chaomei Xiong; Chunping Yin; Jinlan Ruan
Journal:  J Ethnopharmacol       Date:  2014-09-23       Impact factor: 4.360

Review 3.  Endocrine control of benign prostatic hyperplasia.

Authors:  S La Vignera; R A Condorelli; G I Russo; G Morgia; A E Calogero
Journal:  Andrology       Date:  2016-04-18       Impact factor: 3.842

Review 4.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

5.  The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats.

Authors:  Xinying Wu; Ye Gu; Lun Li
Journal:  Toxicol Lett       Date:  2016-11-17       Impact factor: 4.372

6.  Prostatotropic Action of Glycyrrhizic Acid Disodium Salt in Benign Prostatic Hyperplasia Models.

Authors:  S A Nizomov; I V Sorokina; N A Zhukova; S A Borisov; T G Tolstikova; D E Semenov; M A Bakarev
Journal:  Bull Exp Biol Med       Date:  2020-06-02       Impact factor: 0.804

7.  Chrysin attenuates testosterone-induced benign prostate hyperplasia in rats.

Authors:  Sherif M Shoieb; Ahmed Esmat; Amani E Khalifa; Ashraf B Abdel-Naim
Journal:  Food Chem Toxicol       Date:  2017-12-14       Impact factor: 6.023

8.  Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats.

Authors:  Woo-Young Jeon; Ohn Soon Kim; Chang-Seob Seo; Seong Eun Jin; Jung-Ae Kim; Hyeun-Kyoo Shin; Yong-Ung Kim; Mee-Young Lee
Journal:  BMC Complement Altern Med       Date:  2017-08-03       Impact factor: 3.659

9.  Effects of Qianlie Tongqiao Capsule on Bladder Weight and Growth Factors in Bladder Tissue of Rats with Testosterone-Induced Benign Prostatic Hyperplasia.

Authors:  Fan Zhao; Chun-He Zhang; Jun-Feng Yan; Yan-Feng Li; Yi-Jian Yang; Di Sun
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-05       Impact factor: 2.629

10.  Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.

Authors:  Bong Kyun Park; Chang Won Kim; Jeong Eun Kwon; Manorma Negi; Yong Tae Koo; Sang Hun Lee; Dong Hyun Baek; Yoo Hun Noh; Se Chan Kang
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.